<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17981" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atrophic Vaginitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Flores</surname>
            <given-names>Shelley A.</given-names>
          </name>
          <aff>Martin Army Community Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hall</surname>
            <given-names>Carrie A.</given-names>
          </name>
          <aff>Florida Southern College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shelley Flores declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Carrie Hall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17981.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atrophic vaginitis is an inflammatory process that occurs in clients experiencing vaginal atrophy. Vaginal atrophy develops secondary to a lack of estrogen due to menopause. Diagnosis is made clinically based on symptoms. This activity reviews the anatomic and histopathologic changes contributing to vaginal atrophy and the role of the interprofessional team in the evaluation and management of atrophic vaginitis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of atrophic vaginitis.</p></list-item><list-item><p>Assess&#x000a0;symptoms of atrophic vaginitis.</p></list-item><list-item><p>Evaluate&#x000a0;histological changes associated with atrophic vaginitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17981&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17981">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17981.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Genitourinary syndrome of menopause, a group of chronic, progressive, hypoestrogenic conditions, includes vulvovaginal atrophy, atrophic vaginitis, and bladder and urethral dysfunctions. Urogenital tissues, derived from similar embryologic tissues, develop and mature in response to estrogen. In hypoestrogenic states, these tissues undergo physiologic change. Atrophic vaginal changes are caused by thinning vaginal epithelium, decreased vaginal rugae and elasticity, and decreased vaginal secretions. Atrophic vaginitis is a symptomatic inflammatory process involving the thinned vaginal epithelium affecting some pre-menopausal and up to 50% of post-menopausal women.</p>
      </sec>
      <sec id="article-17981.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>A hypoestrogenic state may be part of natural physiological menopause or induced (secondary to surgical, radiation, or chemotherapy treatments). Premenopausal women may develop a temporary hypoestrogenic state while lactating. Other conditions, such as exposure to medications, radiation therapy, chemotherapy, or hypothalamic dysfunction, may also result in a hypoestrogenic state. Medications that may induce a hypoestrogenic state include selective estrogen receptor modulators, selective estrogen receptor degraders, and antigonadotropins. Decreased estrogen levels lead to changes in the vaginal environment, which causes a shift in the normal flora. Typically, there is a decrease in Lactobacillus spp. resulting in overgrowth of skin and rectal pathogens.</p>
      </sec>
      <sec id="article-17981.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>An estimated 10% to 50% of all postmenopausal women develop atrophic vaginitis.<xref ref-type="bibr" rid="article-17981.r1">[1]</xref><xref ref-type="bibr" rid="article-17981.r2">[2]</xref><xref ref-type="bibr" rid="article-17981.r3">[3]</xref>&#x000a0;Additionally, 15% of premenopausal women develop genitourinary syndrome symptoms.&#x000a0;While these numbers are high, the prevalence may be significantly higher than reported, and many women do not discuss their symptoms.<xref ref-type="bibr" rid="article-17981.r4">[4]</xref></p>
      </sec>
      <sec id="article-17981.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The female genitalia, the lower urinary tract, and the surrounding vasculature develop from the same embryologic tissue with similar estrogen receptors. Estrogen receptor alpha is primarily found in the uterus and pituitary gland. The estrogen receptor alpha is present during premenopause and postmenopause. Estrogen receptor beta is primarily found in the ovary. The estrogen receptor beta is present predominately in the premenopausal state, leading to the ovarian failure state experienced in menopause.<xref ref-type="bibr" rid="article-17981.r4">[4]</xref>&#x000a0;Hypoestrogenic state results in the fusion of collagen fibers and fragmentation of elastin fibers in vulvovaginal tissue and decreased squamous cells, resulting in decreased mucosal elasticity and decreased rugae, and narrowing of the vagina.</p>
        <p>Premenopausal vaginal tissues mature in normal estrogen ranges of 30&#x000a0;to 40 pg/ml, which allows for adequate growth of vaginal epithelium with superficial squamous cells containing glycogen. Lactobacilli spp. utilize the glycogen from the cells and convert it into lactic acid, creating a slightly acidic environment with a pH of 3.5 to 5.0. Free glycogen is also associated with lower pH and higher levels of lactobacillus. In menopause, vaginal tissue is exposed to estrogen less than 20pg/ml resulting in fewer superficial squamous epithelial cells with an increase in parabasal cells. The higher concentration of parabasal cells and reduced Lactobacillus spp. leads to decreased lactic acid conversion, producing a higher pH of 5.0 to 7.5 environment. (1,2) The consequence of elevated vaginal pH is a shift in normal flora, <italic toggle="yes">Lactobacilli</italic> spp., and more susceptible to other pathogens such as Gardnerella, Prevoltella, Atopobium, and Streptococcus.<xref ref-type="bibr" rid="article-17981.r2">[2]</xref><xref ref-type="bibr" rid="article-17981.r5">[5]</xref><xref ref-type="bibr" rid="article-17981.r3">[3]</xref></p>
      </sec>
      <sec id="article-17981.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Atrophic pattern histologic findings demonstrate decreased superficial squamous cells, increased parabasal cells, and decreased lactobacilli. However, there are normal to low numbers of neutrophils.<xref ref-type="bibr" rid="article-17981.r6">[6]</xref>&#x000a0;Increased neutrophils are noted in atrophic vaginitis when compared to the vaginal atrophy pattern.<xref ref-type="bibr" rid="article-17981.r1">[1]</xref>&#x000a0;The hypoestrogenic state results in the loss of dermal collagen, elastin fibers, and blood vessels in the lamina propria. These changes result in decreased elasticity and vascularity. Decreased vascularity, in response to low estrogen levels, results in thin friable vaginal mucosa and decreased secretions.</p>
      </sec>
      <sec id="article-17981.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Postmenopausal women are typically older than 50 years old unless they incur induced menopause. Postmenopausal women have low estrogen levels, precipitating genitourinary syndrome symptoms. Symptoms appear in the early to late postmenopausal stage. The STRAW staging system is useful for healthcare members and patients to evaluate menstrual transition and postmenopause.<xref ref-type="bibr" rid="article-17981.r7">[7]</xref>&#x000a0;Atrophic vaginitis symptoms include vulvovaginal dryness, pruritis, dyspareunia, abnormal vaginal discharge, post-coital pain of the labia minora or deeper in the vaginal vault, recurrent urinary tract infections, urethral pain, hematuria, urinary incontinence.<xref ref-type="bibr" rid="article-17981.r1">[1]</xref><xref ref-type="bibr" rid="article-17981.r8">[8]</xref><xref ref-type="bibr" rid="article-17981.r9">[9]</xref>&#x000a0;These symptoms may be progressive, or the patient may have just noticed the changes.</p>
      </sec>
      <sec id="article-17981.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Age-related changes include a decrease in hair distribution and pigment of the hair. Decreased subcutaneous fat leads to a decreased volume of the mons pubis, labia majora, and labia minora. There may be fissuring or other signs of friction of the external genitalia or the introitus. Inflammation may occur, resulting in erythematous patches with or without petechia or friable tissue. Collection of pH, vaginal swabs for the Vaginal Maturation Index, and cultures are obtained before the speculum exam. The exam reveals hypoestrogenic tissue with decreased secretions and elasticity, narrowing the introitus and being more susceptible to friction. Vaginal tissue&#x000a0;is pale pink with diminished vaginal secretions. pH greater than 5.0 or decreased Follicular stimulating hormone is consistent with lower estrogen states. The pH of vaginal secretions should be obtained before the speculum exam. The vaginal&#x000a0;maturation index (VMI) is the proportional relationship between the superficial, intermediate, and parabasal cells of the vaginal tissue. A decrease in estrogen is associated with increased parabasal cells, resulting in lower VMI. The hypoestrogenic state is noted as a VMI of 0&#x000a0;to 49, however, the hyperestrogenic state is noted as a VMI 65&#x000a0;to 100.<xref ref-type="bibr" rid="article-17981.r1">[1]</xref><xref ref-type="bibr" rid="article-17981.r10">[10]</xref></p>
      </sec>
      <sec id="article-17981.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of atrophic vaginitis begins with a trial of intravaginal estrogen. Intravaginal estrogen products, Conjugated estrogen cream, estradiol cream, estradiol tablet, estradiol vaginal ring, and estradiol transdermal patch show equivocal relief of symptoms and improvement in acidification of vaginal tissues.<xref ref-type="bibr" rid="article-17981.r6">[6]</xref><xref ref-type="bibr" rid="article-17981.r7">[7]</xref>&#x000a0;Use the lowest effective dose to reduce systemic estrogen exposure. Taper the estrogen therapy after symptoms and function improve.<xref ref-type="bibr" rid="article-17981.r8">[8]</xref>&#x000a0;Some patients may require maintenance therapy indefinitely. Contraindications to estrogen therapy include a history of estrogen receptor-positive breast cancer, other estrogen-dependent cancers (subtypes of breast and uterine cancers), thromboembolism disorders, liver disease, undiagnosed vaginal bleeding, endometrial hyperplasia, heart disease, pregnancy, migraines with aura, or allergy to the estrogen or the carrier product.<xref ref-type="bibr" rid="article-17981.r11">[11]</xref>&#x000a0;The vaginal maturation index may be used as a clinical measurement to evaluate the response to estrogen therapy.&#x000a0;<italic toggle="yes">Lactobacillus</italic> predominance is associated with fewer genital symptoms compared to a change in pH.<xref ref-type="bibr" rid="article-17981.r2">[2]</xref>&#x000a0;Additional or alternative therapy includes selective estrogen receptor modulators, tissue-selective estrogen complexes, estriol, platelet-rich plasma, herbals, and other natural products.<xref ref-type="bibr" rid="article-17981.r9">[9]</xref>&#x000a0;Ospemifene, a selective estrogen receptor modulator, is approved by the FDA for adjunctive therapy in patients with dyspareunia or for use in patients who are not candidates for estrogen therapy.&#x000a0;A patient may use lubricants for symptomatic improvement or if contraindicated to estrogen therapy. Lubricants can improve symptoms; however, no chemical or histologic changes occur. Other non-hormonal forms of treatments include fractional micro-ablative carbon-dioxide laser therapy and transcutaneous temperature-controlled radiofrequency with external and internal treatments that improve vaginal dryness, vulvovaginal laxity, and dyspareunia for 6&#x000a0;to 12 months.<xref ref-type="bibr" rid="article-17981.r12">[12]</xref><xref ref-type="bibr" rid="article-17981.r13">[13]</xref><xref ref-type="bibr" rid="article-17981.r14">[14]</xref><xref ref-type="bibr" rid="article-17981.r15">[15]</xref><xref ref-type="bibr" rid="article-17981.r16">[16]</xref></p>
      </sec>
      <sec id="article-17981.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differentials include vaginal atrophy, vulvovaginal atrophy, vulvovaginal lichen planus or sclerosis, vulvar dermatitis, vulvovaginal candidiasis, vulvodynia, inflammatory vaginitis without atrophy, desquamative inflammatory vaginitis, vulvovaginal neoplasm, sexually transmitted infection, other infections, and urogenital dysfunction.</p>
      </sec>
      <sec id="article-17981.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Microablative carbon-dioxide laser therapy has been noted to improve histologic changes in the lamina propria with the remodeling of collagen fibers and blood vessels and improve the vaginal flora with increased <italic toggle="yes">Lactobacillus</italic> spp.<xref ref-type="bibr" rid="article-17981.r15">[15]</xref><xref ref-type="bibr" rid="article-17981.r17">[17]</xref></p>
        <p>Radiofrequency temperature therapy shows potential as an alternative treatment for atrophic vaginitis. However, due to the small study sizes, follow-up studies are needed to evaluate the histological changes that improved the regeneration of collagen and blood vessels.<xref ref-type="bibr" rid="article-17981.r12">[12]</xref><xref ref-type="bibr" rid="article-17981.r13">[13]</xref><xref ref-type="bibr" rid="article-17981.r14">[14]</xref></p>
      </sec>
      <sec id="article-17981.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Many women see improvement with the use of intravaginal estrogen. Those refractory to treatment or who experience incomplete resolution may start adjunctive therapy with ospemifene. Risk factors include no vaginal births, therefore, no stretching of the vaginal canal. Cigarette smoking causes vasoconstriction, which decreases secretions and exacerbates symptoms.</p>
      </sec>
      <sec id="article-17981.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Untreated atrophic vaginitis leads to persistent pruritis, which may cause scarring from scratching. Thinned mucosa may result in abrasions or fissures. The patient may continue to have other genitourinary complaints.</p>
      </sec>
      <sec id="article-17981.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Atrophic vaginitis is an inflammatory condition associated with low estrogen levels. Pre-menopausal women may experience symptoms that postmenopausal women more commonly experience. Treatment is typically initiated with localized estrogen therapy to provide symptom relief. Adjunctive therapy with estrogen modulator receptors or radiofrequency treatment may further improve symptoms.</p>
      </sec>
      <sec id="article-17981.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Atrophic vaginitis is not a life-threatening disease, but it can significantly negatively affect patients' quality of life if not diagnosed and treated appropriately. Interprofessional communication and patient education are essential. The condition can be recognized and treated by multiple clinicians, including primary care, obstetricians/gynecologists, dermatologists, and surgeons. A proper diagnosis can be challenging without a dedicated history taking and physical exam, and misdiagnosis can lead to unnecessary referrals and procedures. With adequate interprofessional communication and patient education, atrophic vaginitis can be diagnosed and treated for improved patient outcomes.</p>
      </sec>
      <sec id="article-17981.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17981&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17981">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/atrophic-vaginitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17981">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17981/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17981">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17981.s17">
        <title>References</title>
        <ref id="article-17981.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stika</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Atrophic vaginitis.</article-title>
            <source>Dermatol Ther</source>
            <year>2010</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>514</fpage>
            <page-range>514-22</page-range>
            <pub-id pub-id-type="pmid">20868405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Forney</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Apr</month>
            <day>22</day>
            <volume>6</volume>
            <fpage>24380</fpage>
            <pub-id pub-id-type="pmid">27103314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brotman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Shardell</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gajer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fadrosh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Viscidi</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ravel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gravitt</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.</article-title>
            <source>Menopause</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1321</fpage>
            <page-range>1321-1330</page-range>
            <pub-id pub-id-type="pmid">30358729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandhi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dagur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cali</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Genitourinary syndrome of menopause: an&#x000a0;overview of clinical manifestations, pathophysiology, etiology, evaluation, and&#x000a0;management.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>215</volume>
            <issue>6</issue>
            <fpage>704</fpage>
            <page-range>704-711</page-range>
            <pub-id pub-id-type="pmid">27472999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirmonsef</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hotton</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burgad</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Landay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ravel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spear</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>Free glycogen in vaginal fluids is associated with Lactobacillus colonization and low vaginal pH.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>e102467</fpage>
            <pub-id pub-id-type="pmid">25033265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heller</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bittman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Does a diagnosis of atrophic vaginitis on Papanicolaou test signify the presence of inflammation?</article-title>
            <source>Menopause</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>814</fpage>
            <page-range>814-5</page-range>
            <pub-id pub-id-type="pmid">25535962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harlow</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rebar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sluss</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>de Villiers</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>STRAW + 10 Collaborative Group</collab>
            </person-group>
            <article-title>Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>1159</fpage>
            <page-range>1159-68</page-range>
            <pub-id pub-id-type="pmid">22344196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rioux</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hepburn</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>17&#x003b2;-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.</article-title>
            <source>Menopause</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1208</fpage>
            <page-range>1208-1213</page-range>
            <pub-id pub-id-type="pmid">30358715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Enkhbold</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials.</article-title>
            <source>J Menopausal Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">29765921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Vaginitis: Beyond the Basics.</article-title>
            <source>Obstet Gynecol Clin North Am</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-177</page-range>
            <pub-id pub-id-type="pmid">28499528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suckling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lethaby</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Local oestrogen for vaginal atrophy in postmenopausal women.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2006</year>
            <month>Oct</month>
            <day>18</day>
            <issue>4</issue>
            <fpage>CD001500</fpage>
            <pub-id pub-id-type="pmid">17054136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alinsod</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Transcutaneous Temperature Controlled Radiofrequency for Atrophic Vaginitis and Dyspareunia.</article-title>
            <source>J Minim Invasive Gynecol</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>22</volume>
            <issue>6S</issue>
            <fpage>S226</fpage>
            <page-range>S226-S227</page-range>
            <pub-id pub-id-type="pmid">27679110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanaman Wilson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Calame</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device.</article-title>
            <source>Dermatol Surg</source>
            <year>2018</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>705</fpage>
            <page-range>705-713</page-range>
            <pub-id pub-id-type="pmid">29701623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leibaschoff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Izasa</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miklos</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the Treatment of Menopausal Vaginal/Genitourinary Symptoms.</article-title>
            <source>Surg Technol Int</source>
            <year>2016</year>
            <month>Oct</month>
            <day>26</day>
            <volume>29</volume>
            <fpage>149</fpage>
            <page-range>149-159</page-range>
            <pub-id pub-id-type="pmid">27608749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwon</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Seok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bak</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mun</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Fractional CO<sub>2</sub> laser treatment for vaginal laxity: A preclinical study.</article-title>
            <source>Lasers Surg Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>940</fpage>
            <page-range>940-947</page-range>
            <pub-id pub-id-type="pmid">29733104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Athanasiou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitsouni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grigoriadis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zacharakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Salvatore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Protopapas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loutradis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.</article-title>
            <source>Menopause</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>248</fpage>
            <page-range>248-255</page-range>
            <pub-id pub-id-type="pmid">30252804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17981.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Athanasiou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitsouni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antonopoulou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zacharakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salvatore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Grigoriadis</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women.</article-title>
            <source>Climacteric</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-8</page-range>
            <pub-id pub-id-type="pmid">27558459</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
